Literature DB >> 8380193

Down-regulation of angiotensin II receptor subtypes and desensitization of cyclic GMP production in neuroblastoma N1E-115 cells.

L P Reagan1, X Ye, C H Maretzski, S J Fluharty.   

Abstract

Murine neuroblastoma N1E-115 cells possess membranous receptors for the octapeptide angiotensin II (AngII) whose density is substantially increased by in vitro differentiation. Incubation of differentiated N1E-115 cells with AngII produced a rapid decrease in receptor density, but did not alter the affinity of these receptors for either 125I-AngII or the high-affinity antagonist 125I-[Sarc1,Ile8]-AngII. This apparent down-regulation was dose related with an ED50 of 1 nM, and maximal decreases of approximately 90% were obtained with 100 nM AngII. Receptor loss from differentiated cell membranes was unaffected by incubations of membranes obtained from agonist-exposed cells with non-hydrolyzable analogues of GTP for 60 min at 37 degrees C to ensure dissociation of the ligand. Partial loss of AngII receptors was apparent within 5 min of agonist exposure, whereas maximal declines were not observed until 30 min. This temporal pattern resulted from a preferential decrease in the AT1 receptor subtype during the first 5 min, followed by a decline in both AT1 and AT2 receptors with longer periods of agonist exposure. The loss of membranous receptors was reversible with partial recovery observed after 4 h, and with nearly full recovery observed 18 h after exposure of the cells to AngII. However, the long-term recovery of receptor density was blocked by the protein synthesis inhibitor, cycloheximide. The heptapeptide angiotensin III produced a similar down-regulation of receptors, and the high-affinity antagonist [Sarc1,Thr8]-AngII blocked agonist-induced down-regulation. Finally, the apparent loss of cell surface AngII receptors decreased the ability of AngII to stimulate cyclic GMP production within intact N1E-115 cells.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8380193     DOI: 10.1111/j.1471-4159.1993.tb05818.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  8 in total

1.  Importance of input perturbations and stochastic gene expression in the reverse engineering of genetic regulatory networks: insights from an identifiability analysis of an in silico network.

Authors:  Daniel E Zak; Gregory E Gonye; James S Schwaber; Francis J Doyle
Journal:  Genome Res       Date:  2003-11       Impact factor: 9.043

2.  AT2 receptor-mediated vasodilation in the mouse heart depends on AT1A receptor activation.

Authors:  Joep H M van Esch; Martin P Schuijt; Jilani Sayed; Yawar Choudhry; Thomas Walther; A H Jan Danser
Journal:  Br J Pharmacol       Date:  2006-05-08       Impact factor: 8.739

3.  Cardiac phenotype and angiotensin II levels in AT1a, AT1b, and AT2 receptor single, double, and triple knockouts.

Authors:  Joep H M van Esch; Florian Gembardt; Anja Sterner-Kock; Silvia Heringer-Walther; Thu H Le; Dirk Lassner; Theo Stijnen; Thomas M Coffman; Heinz-Peter Schultheiss; A H Jan Danser; Thomas Walther
Journal:  Cardiovasc Res       Date:  2010-01-12       Impact factor: 10.787

4.  Angiotensin converting enzyme inhibition does not affect the response to exogenous angiotensin II in the human forearm.

Authors:  D Lyons; D Stewart; J Webster; N Benjamin
Journal:  Br J Clin Pharmacol       Date:  1994-11       Impact factor: 4.335

5.  Potentiation of purinergic transmission by angiotensin in prostatic rat vas deferens.

Authors:  C S Sum; D C Wan; W T Cheung
Journal:  Br J Pharmacol       Date:  1996-07       Impact factor: 8.739

6.  Angiotensin converting enzyme inhibition does not affect response to exogenous angiotensin II in the forearm of mild-moderate hypertensive patients.

Authors:  D Lyons; J Webster; N Benjamin
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

7.  Angiotensin II AT2 receptors are functionally coupled to protein tyrosine dephosphorylation in N1E-115 neuroblastoma cells.

Authors:  C Nahmias; S M Cazaubon; M M Briend-Sutren; D Lazard; P Villageois; A D Strosberg
Journal:  Biochem J       Date:  1995-02-15       Impact factor: 3.857

8.  Ability of angiotensin II to modulate striatal dopamine release via the AT1 receptor in vitro and in vivo.

Authors:  D C Brown; L J Steward; J Ge; N M Barnes
Journal:  Br J Pharmacol       Date:  1996-05       Impact factor: 8.739

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.